Characteristics of Ongoing Clinical Trials of Psychogenic Substances for Psychiatric Disorders

Ongoing clinical trials of psychogenic substances for psychiatric disorders are largely concentrated at select institutions and primarily focus on psilocybin and ketamine. The majority lack clear disclosure of funding sources, highlighting a need for enhanced transparency to build trust and facilitate the ethical advancement of this rapidly evolving area of psychiatric research.